Prostate cancer screening: A primary care survey

Samuel Deem, Brian DeFade, Josh Lohri, James P. Tierney, Asmita Modak, Mary Emmett
DOI: 10.4236/health.2010.210173                

Abstract

Prostate cancer is the most common intrinsic cancer in men and the 2nd most common cause of cancer related death in men over fifty years of age. The benefit of early screening for prostate cancer is yet to be proven. Multiple organizations currently offer recommendations regarding prostate cancer screening. Prostate Specific Antigen (PSA) testing was introduced into widespread use in the late 80’s and its role in screening is debatable. We surveyed by mail every primary care physician in West Virginia who has a state license. Results from 438 respondents indicated that the American Cancer Society (ACS) guidelines were most commonly used and that PSA testing does seem to be a good screening test. We present the results and discuss the different points of view regarding prostate cancer screening.

Keywords

Prostate; Cancer; Screening; PSA; Guidelines; Survey

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	U.S. Cancer Statistics Working Group (2010) United States cancer statistics: 1999–2006 incidence and mortality web-based report. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta. www.cdc.gov/uscs
[2]	NCCN Clinical Practice Guidelines in Oncology (2010) Prostate cancer early detection. www.nccn.org
[3]	Bostwick, D.G., Crawford, E.D., Higano, C.S., Roach, M., Eds. (2005) American cancer society’s complete guide to prostate cancer. American Cancer Society, Atlanta.
[4]	Sirovich, B.E., Schwartz, L.M. and Woloshin, S. (2003) Screening men for prostate and colorectal cancer in the United States, does practice reflect the evidence? Journal of the American Medical Association, 289, 1414-1420.
[5]	Lawson, D.A., Simoes, E.J., Sharp, D., et al. (1998) Prostate cancer screening - A physician survey in Missouri. Journal of Community Health, 23(5), 347-358.
[6]	Fowler, F.J., Bin, L., Collins, M.M., et al. (1998) Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. American Journal of Medicine, 104(6), 526-532.
[7]	Roberts, R.O., Bergstralh, E.J., Katusic, S.K., et al. (1999) Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. Journal of Urology, 161(2), 529-533.
[8]	Bartsch, G., Horninger, W., Klocker, H., et al. (2001) Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 58(3), 417-424.
[9]	Tarone, R.E., Chu, K.C. and Brawley, O.W. (2000) Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology, 11(2), 167-170.
[10]	Andriole, G.L., Levin, D.L., Crawford, E.D., et al. (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: Findings from the initial screening round of a randomized trial. Journal of the National Cancer Institute, 97(6), 433-438.
[11]	Andriole, G.L., Crawford, E.D. and Grubb, R.L. (2009) Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine, 360(13), 1310-1319.
[12]	Shroder, F.H., Hugosson, J., Roobol, M.J., et al. (2009) Screening and prostate cancer mortality in a randomized European study. The New England Journal of Medicine, 360(13), 1320-1328.
[13]	McKnight, J.T., Tietze, P.H., Adcock, B.B., et al. (1996) Screening for prostate cancer: a comparison of urologists and primary care physicians. Southern Medical Journal, 89(9), 885-888.
[14]	Hicks, R.J., Hamm, R.M. and Bemben, D.A. (1995) Prostate cancer screening. What family physicians believe is best. Archives of Family Medicine, 4(4), 317-322.
[15]	Curran, V., Solberg, S., Mathews, M., et al. (2005) Prostate cancer screening attitudes and continuing education needs of primary care physicians. Journal of Cancer Education, 20(3), 162-166.
[16]	Moran, W.P., Cohen, S.J., Preisser, J.S., et al. (2000) Factors influencing use of the prostate-specific antigen screening test in primary care. American Journal of Managed Care, 6(3), 315-324.
[17]	Stenner, J., Holthaus, K., Mackenzie, S.H., et al. (1998) The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology, 51(3), 455-459.
[18]	Lippman, S.M., Klein, E.A., Goodman, P.J., et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancer – The selenium and vitamin E cancer prevention trial (SELECT). Journal of the American Medical Association, 301(1), 39-51.
[19]	Thompson, I.M., Goodman, P.J., Tangen, C.M., et al. (2003) The influence of Finasteride on the development of prostate cancer. The New England Journal of Medicine, 349(3), 213-222.
[20]	Kramer, B.S., Hagerty, K.L., Justman, S., et al. (2009) Use of 5α-Reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American urological association 2008 clinical practice guideline. Journal of Urology, 181(4), 1642-1657.